Tag: offering

London, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- MGPD Finance Limited, doing business as HashJ, today announced the official release of a new short-term participation contract focused on Bitcoin (BTC), designed for users navigating a market at a technical crossroads. The launch follows a period of directional indecision in the BTC market, as traders assess whether recent price action marks a consolidation phase or the early stage of a sustained move.

SINGAPORE, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ostium, a decentralized trading platform, has announced the launch of a new leveraged trading instrument: 0DTE perpetuals for equities. The instrument combines intraday expiry with perpetual structure, offering day traders up to 100x leverage on individual stocks during market hours — a structural innovation aimed at addressing the limitations of traditional options and CFDs.

Fullerton, CA, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Search Business Group, a Latino-owned digital marketing agency based in Southern California, announced the launch of its new Generative Engine Optimization (GEO) services to help doctors, dentists, and veterinary practices rank on AI-driven search platforms like ChatGPT, Perplexity, and Gemini. The new offering positions providers across the region to stay visible and competitive as patient search behavior shifts toward generative AI platforms.

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a “Fund” and, collectively, the “Funds”) have declared a monthly distribution for each Fund’s common shares as summarized below.

IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.